Sinotau Obtains Rights in China for the Radiopharmaceutical Diagnostic Agent Lymphoseek®

Company News

Sep. 4th, 2014. Sinotau Pharmaceuticals Group has entered into an agreement with Navidea Biopharmaceuticals Inc., US company, for the exclusive China distribution rights of Lymphoseek® Injection, a patented radiopharmaceutical diagnostic agent. 

Navidea: “Lymphoseek® Injection is the first and only FDA-approved receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients with breast cancer, melanoma and head and neck cancer patients with oral cavity carcinoma. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek is approved by the U.S. Food and Drug Administration (FDA) for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma and for use in guiding sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. The Company anticipates continuing development of Lymphoseek into other solid tumor areas”.